Literature DB >> 3016178

Enhanced noradrenergic neuronal activity increases homovanillic acid levels in cerebrospinal fluid.

H Scheinin.   

Abstract

Idazoxan, a highly specific and selective alpha 2-adrenoceptor antagonist, caused a dose-dependent increase in the concentration of homovanillic acid (HVA) a metabolite of 3,4-dihydroxyphenylethylamine, in cisternal CSF of freely moving rats. This increase in HVA level could be antagonized by the alpha 2-adrenoceptor agonist medetomidine. The increase was directly proportional to the concurrent elevation in level of 3-methoxy-4-hydroxyphenylglycol, a metabolite of noradrenaline, in the CSF of individual rats and followed a similar time course. It is suggested that the HVA level in CSF may be increased under conditions of enhanced noradrenergic activity and that, in such situations, it reflects noradrenergic rather than dopaminergic neuronal activity. Care should be taken, therefore, when changes in central dopaminergic activity are assessed by measurements of HVA level in CSF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016178     DOI: 10.1111/j.1471-4159.1986.tb00662.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms.

Authors:  M B Bowers; M J Bannon; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  A new approach to biochemical evaluation of brain dopamine metabolism.

Authors:  I J Kopin; J H White; K Bankiewicz
Journal:  Cell Mol Neurobiol       Date:  1988-06       Impact factor: 5.046

Review 3.  The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

Authors:  R Miller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Sedative and cardiovascular effects of medetomidine, a novel selective alpha 2-adrenoceptor agonist, in healthy volunteers.

Authors:  M Scheinin; A Kallio; M Koulu; J Viikari; H Scheinin
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.